GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats - PubMed (original) (raw)
GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats
Tomoaki Inoue et al. Atherosclerosis. 2015 May.
Abstract
Objective: Accumulating evidence has implicated that GLP-1 may have a beneficial effect on cardiovascular but the mechanism is not fully understood. Here we show that GLP-1 analog, liraglutide, inhibits cardiac steatosis, oxidative stress and apoptosis in streptozotocin (STZ)-induced type 1 diabetic rats, via activation of AMPK-Sirt1 pathway.
Methods: Diabetic rats were treated with subcutaneous injections of liraglutide (0.3 mg/kg/12 h) for 4 weeks. Myocardial steatosis (detected by oil red O staining and myocardial triglyceride and diacylglycerol (DAG) contents assay), expression of protein kinase C (PKC), heart NAD(P)H oxidase activity, oxidative stress markers (8-hydroxy-2'-deoxyguanosine staining), apoptosis (TUNEL analysis) and genes that affect apoptosis and lipid metabolism were evaluated.
Results: Administration of liraglutide did not affect plasma glucose and insulin levels or body weights in STZ-induced diabetic rats, but normalized myocardial steatosis, expression of PKC, NAD(P)H oxidase activity, oxidative stress markers and apoptosis, all of which were significantly increased in diabetic hearts. Additionally, expression of genes mediating lipid uptake, synthesis and oxidation were increased in the diabetic hearts, and these increases were all reduced by liraglutide. In addition, liraglutide increased expression of Sirt1 and phosphorylated AMPK in the diabetic hearts.
Conclusions: Liraglutide may have a beneficial effect on cardiac steatosis, DAG-PKC-NAD(P)H pathway, oxidative stress and apoptosis via activation of AMPK-Sirt1 pathway, independently of a glucose-lowering effect.
Keywords: Cardiac steatosis; Diabetic cardiomyopathy; Glucagon-like peptide-1; Oxidative stress; Protein kinase C.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N, Takayanagi R. Hendarto H, et al. Metabolism. 2012 Oct;61(10):1422-34. doi: 10.1016/j.metabol.2012.03.002. Epub 2012 May 1. Metabolism. 2012. PMID: 22554832 - Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Batchuluun B, et al. Atherosclerosis. 2014 Jan;232(1):156-64. doi: 10.1016/j.atherosclerosis.2013.10.025. Epub 2013 Nov 5. Atherosclerosis. 2014. PMID: 24401231 - Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway.
Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Mito S, Harima M, Thandavarayan RA, Suzuki K, Nagata M, Takagi R, Watanabe K. Soetikno V, et al. Eur J Pharm Sci. 2012 Oct 9;47(3):604-14. doi: 10.1016/j.ejps.2012.04.018. Epub 2012 Apr 28. Eur J Pharm Sci. 2012. PMID: 22564708 - An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M. Palomer X, et al. Int J Cardiol. 2013 Oct 9;168(4):3160-72. doi: 10.1016/j.ijcard.2013.07.150. Epub 2013 Aug 6. Int J Cardiol. 2013. PMID: 23932046 Review. - Molecular mechanisms of cardiac pathology in diabetes - Experimental insights.
Varma U, Koutsifeli P, Benson VL, Mellor KM, Delbridge LMD. Varma U, et al. Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt B):1949-1959. doi: 10.1016/j.bbadis.2017.10.035. Epub 2017 Nov 3. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 29109032 Review.
Cited by
- Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects.
Lymperopoulos A, Borges JI, Stoicovy RA. Lymperopoulos A, et al. Pharmaceutics. 2024 May 22;16(6):693. doi: 10.3390/pharmaceutics16060693. Pharmaceutics. 2024. PMID: 38931817 Free PMC article. Review. - Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists.
Boshchenko AA, Maslov LN, Mukhomedzyanov AV, Zhuravleva OA, Slidnevskaya AS, Naryzhnaya NV, Zinovieva AS, Ilinykh PA. Boshchenko AA, et al. Int J Mol Sci. 2024 Apr 30;25(9):4900. doi: 10.3390/ijms25094900. Int J Mol Sci. 2024. PMID: 38732142 Free PMC article. Review. - Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression.
Yan M, Lin K, Huang D, Li J, Qu X, Chen K. Yan M, et al. Endocrine. 2024 Jun;84(3):969-979. doi: 10.1007/s12020-024-03823-2. Epub 2024 Apr 22. Endocrine. 2024. PMID: 38647981 - The crucial relationship between miRNA-27 and CSE/H2S, and the mechanism of action of GLP-1 in myocardial hypertrophy.
Gao S, Li Y, Liu MM, Xiong X, Cui CP, Huo QJ, Li KX, Sun X, Zhang R, Wu D, Li BY. Gao S, et al. Int J Med Sci. 2024 Mar 31;21(5):965-977. doi: 10.7150/ijms.93720. eCollection 2024. Int J Med Sci. 2024. PMID: 38616996 Free PMC article. - Emerging role of antidiabetic drugs in cardiorenal protection.
Fu WJ, Huo JL, Mao ZH, Pan SK, Liu DW, Liu ZS, Wu P, Gao ZX. Fu WJ, et al. Front Pharmacol. 2024 Feb 6;15:1349069. doi: 10.3389/fphar.2024.1349069. eCollection 2024. Front Pharmacol. 2024. PMID: 38384297 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical